IPO Guru

IPO Listed — 02 Apr 2026

Listing Price: ₹400

vs Issue Price ₹392 +₹8 (+2.04%)

Sai Parenteral's IPO GMP History | Listing Price ₹400 & Kostak Rate

IPO
Final GMP
₹ 0
--
Final Kostak
Retail ₹ 0
SHNI ₹ 0
BHNI ₹ 0
Final Sub. to Sauda
Retail ₹ 0
SHNI ₹ 0
BHNI ₹ 0

Sai Parenteral's IPO has been listed on April 2, 2026 at a listing price of ₹400, against the issue price of ₹392 — a gain of ₹8 (+2.04%). The GMP peaked at ₹00 on 1 April 2026 and reached a low of ₹00 on 1 April 2026. The day-wise GMP trend below shows how grey market sentiment evolved from subscription to listing.

Sai Parenteral's IPO raised ₹409 Cr. through its IPO at a price band of ₹372 to ₹392 per share, with a lot size of 38 shares. The IPO was open for subscription from 24 Mar 2026 to 27 Mar 2026.

GMP Trend Chart

Day-wise GMP Trend

Date GMP ↑↓ % Kostak Sub. Sauda
01 Apr 2026 ₹ 0 -- ₹ 0 ₹ 0
31 Mar 2026 ₹ 0 -- ₹ 0 ₹ 0
30 Mar 2026 ₹ 0 -- ₹ 0 ₹ 0
29 Mar 2026 ₹ 0 -- ₹ 0 ₹ 0
28 Mar 2026 ₹ 0 -- ₹ 0 ₹ 0
25 Mar 2026 ₹ 0 -- ₹ 0 ₹ 0
24 Mar 2026 ₹ 0 -- ₹ 0 ₹ 0
23 Mar 2026 ₹ 0 -- ₹ 0 ₹ 0
21 Mar 2026 ₹ 0 -- ₹ 0 ₹ 0
20 Mar 2026 ₹ 0 -- ₹ 0 ₹ 0
19 Mar 2026 ₹ 0 -- ₹ 0 ₹ 0
18 Mar 2026 ₹ 0 -- ₹ 0 ₹ 0

Sai Parenteral's IPO Dates

Event Date
Open Date 24 Mar, 2026
Close Date 27 Mar, 2026
Allotment Date 30 Mar, 2026
Refund Date 01 Apr, 2026
Credit to Demat 01 Apr, 2026
Listing Date 02 Apr, 2026

Sai Parenteral's IPO Actual Listing Price

Basis Value
Issue Price ₹392
Actual Listing Price ₹400 (+2.04%)
Listing Gain / Loss +₹8 per share
Listing Date 02 Apr, 2026

Is Sai Parenteral's IPO GMP Reliable?

Grey market premium for Sai Parenteral's IPO should be interpreted with caution. The GMP is an unregulated, unofficial market not governed by SEBI. Here's how to read the current signal:

  • Subscription rate matters: A high GMP paired with strong subscription — especially QIB (Qualified Institutional Buyer) oversubscription — is a more reliable bullish signal than GMP alone. Read our in-depth analysis: GMP vs Subscription Data — Which Predicts Listing Gains Better?
  • Timing matters: GMP in the first 1–2 days of subscription is less reliable. GMP on the final subscription day and the day before listing tends to be the most accurate predictor.
  • Grey market is thin: For smaller IPOs, even a handful of large orders can swing the GMP significantly. Treat low-volume GMP signals with extra caution.
  • Cross-check before acting: Review the Sai Parenteral's IPO full review for a fundamentals-based assessment before making any grey market trades.

Sai Parenteral's IPO IPO Kostak Rate Explained

The Kostak rate for Sai Parenteral's IPO was not active during the subscription period, as no grey market premium was established. Kostak is the fixed amount a grey market buyer pays for an IPO application regardless of allotment outcome.

The Subject to Sauda price was not active for this IPO. Subject to Sauda only applies if allotment is confirmed — the buyer pays a premium on top of the issue price per lot allotted.

Grey market trading is unofficial and unregulated by SEBI. Proceed with full awareness of the associated risks.

About Sai Parenteral's IPO

Sai Parenteral Limited is an Indian pharmaceutical company engaged in the manufacturing of a wide range of sterile formulations. The company was established with the objective of providing high-quality and affordable injectable medicines, catering to both domestic and international markets. Over the years, it has built a strong presence in the pharma industry by focusing on compliance, quality standards, and consistent product delivery. The company is promoted by experienced professionals with deep domain knowledge in pharmaceutical manufacturing and regulatory requirements, which has helped in establishing a reliable operational framework.

The company’s product portfolio primarily includes injectable formulations such as antibiotics, analgesics, and other therapeutic drugs used in hospitals and healthcare institutions. It follows a business model that combines contract manufacturing and direct marketing, enabling it to serve both institutional buyers and third-party clients. Sai Parenteral emphasises quality control, modern manufacturing facilities, and adherence to regulatory standards, which supports its long-term growth. By maintaining strong relationships with clients and focusing on operational efficiency, the company aims to expand its footprint in the competitive pharmaceutical sector.

Frequently Asked Questions about Sai Parenteral's IPO

What is the GMP of Sai Parenteral's IPO?

The current Grey Market Premium (GMP) of Sai Parenteral's IPO is not yet started or active in the market.

What is the Kostak Price of Sai Parenteral's IPO?

Kostak rate is the profit made by selling an IPO application before allotment. The current Kostak rate for Sai Parenteral's IPO is : Retail: ₹ 0, SHNI: ₹ 0, BHNI: ₹ 0.

What is the Subject to Sauda Price of Sai Parenteral's IPO?

Subject to Sauda is the premium amount decided if the allotment is confirmed. The current Subject to Sauda rate is : Retail: ₹ 0, SHNI: ₹ 0, BHNI: ₹ 0.

What was the actual listing price of Sai Parenteral's IPO?

Sai Parenteral's IPO listed on April 2, 2026 at ₹400, against the issue price of ₹392 — a gain of +2.04%.

How did the GMP of Sai Parenteral's IPO trend before listing?

The GMP of Sai Parenteral's IPO was stable in its final days before listing. The GMP peaked at ₹00 on 1 April 2026. View the day-wise table above for the complete GMP history.

Explore Sai Parenteral's IPO Further

For a complete picture before making your investment decision, explore these resources:

Discussion 0

💡
Commenting as
Markdown supported: **bold**, _italics_

No comments yet

Be the first to share your thoughts!

Advertisement